JNJ 61187165

Drug Profile

JNJ 61187165

Alternative Names: Ad26 RSV FA2; Ad26.RSV.FA2; JNJ-61187165-AAA; JNJ61187165

Latest Information Update: 10 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Crucell Holland
  • Developer Janssen Vaccines and Prevention B.V
  • Class Respiratory syncytial virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Respiratory syncytial virus infections

Most Recent Events

  • 01 Sep 2016 Crucell Holland completes a phase I trial for Respiratory syncytial virus infections (In volunteers) in USA (NCT02561871)
  • 01 Sep 2015 Phase-I clinical trials in Respiratory syncytial virus infections (Prevention, In volunteers) in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top